{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:24:21Z","timestamp":1793492661841,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamaneurol.2021.4161","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T11:01:13Z","timestamp":1637578873000},"page":"13","source":"Crossref","is-referenced-by-count":601,"title":["Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease"],"prefix":"10.1001","volume":"79","author":[{"given":"Stephen","family":"Salloway","sequence":"first","affiliation":[{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Chalkias","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Institutes of Healthcare Engineering and Neurology, University College London, London, United Kingdom"},{"name":"Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burkett","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Barakos","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center, San Francisco"},{"name":"Bioclinica, Newark, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Purcell","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center, San Francisco"},{"name":"Bioclinica, Newark, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Suhy","sequence":"additional","affiliation":[{"name":"Bioclinica, Newark, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Forrestal","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Umans","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanfang","family":"Wang","sequence":"additional","affiliation":[{"name":"Cytel Inc, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Singhal","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Budd Haeberlein","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smirnakis","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi210073r1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease.","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"noi210073r2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","article-title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer\u2019s disease.","volume":"2","author":"Carlson","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"24","key":"noi210073r3","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"noi210073r4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease.","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"noi210073r5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease.","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi210073r6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi210073r7","first-page":"255","article-title":"Clinical development of aducanumab, an anti-a\u00df human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s disease.","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"21","key":"noi210073r8","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"noi210073r9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"noi210073r10","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities.","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"noi210073r11","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis.","volume":"87","author":"Arrighi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"noi210073r12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways.","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"noi210073r13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis.","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi210073r14","first-page":"S105","article-title":"Vascular alterations in PDAPP mice after anti-A\u00df immunotherapy: implications for amyloid-related imaging abnormalities.","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"7618","key":"noi210073r15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u00df plaques in Alzheimer\u2019s disease.","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"3","key":"noi210073r18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi210073r19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"2","key":"noi210073r20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients.","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"noi210073r21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"noi210073r22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","article-title":"Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.","volume":"74","author":"Linn","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"noi210073r23","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE e4\/e4 patient treated with aducanumab.","volume":"12","author":"VandeVrede","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"noi210073r24","first-page":"398","article-title":"Aducanumab: appropriate use recommendations.","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"noi210073r16","author":"Budd Haeberlein","year":"2021"},{"key":"noi210073r17","author":"Chalkias","year":"2021"},{"key":"noi210073r25","unstructured":"A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer's disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. ClinicalTrials.gov identifier: NCT04241068. Updated September 5, 2021. Accessed September 5, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04241068"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2786606\/jamaneurology_salloway_2021_oi_210073_1641404428.53594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:05:43Z","timestamp":1641812743000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2786606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}